Clinical Trial Update: A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma [Phase 1]

View source ↗

Summary

This Phase I trial investigates SS1 (dsFv) PE38 combined with paclitaxel, carboplatin, and bevacizumab in patients with unresectable non-small cell lung adenoca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• SS1 (dsFv) PE38 (SS1(dsFv) PE38)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Non-Small Cell Lung Cancer, Adenocarcinoma | Phase 1 | Status: COMPLETED